Nyhet -

Maria Forss selected in Swedish Initiative for Women Board Members

Wednesday, 01 July 2009


PULS's Head of Business Development, Maria Forss, is one of the 200 women selected by Maud Olofsson, the Minister for Enterprise and Energy and Deputy Prime Minister, in collaboration with ALMI Företagspartner, to participate in the Styrelsekraft program. This is a national mentoring program targeting qualified and experienced women who have the ambition to be board members of both private and public companies.

The Styrelsekraft program will run for one year. Each participant is matched with a mentor and will participate in networking meetings. She will also receive a scholarship for Board-level education.

Maria Forss says "I am really excited to be given this opportunity, especially since so many qualified women applied to the program. This gives me the chance to broaden both my theoretical knowledge and practical experience, as well as giving me an external mentor and expanding my network".

Maria Forss has a Master of Science of in Business Administration and has been part of the senior management team at PULS since August 2008. Forss is also the project manager for DuoCort Pharma AB and a member of the board of Laccure AB.

 

Ämnen

  • Medicinsk forskning

Kategorier

  • maria forss
  • styrelsekraft
  • duocort pharma
  • almi
  • laccure
  • p.u.l.s. ab

Kontakter

Relaterat innehåll

  • New chronotherapy for Addison´s disease

    Helsingborg June 29th 2009- DuoCort publishes data from its Phase I study for the rare and life threatening disease adrenal insufficiency. The release profile of DuoCort’s new form of treatment with once-a-day hydrocortisone dosing resembles the physiological secretion pattern. The data is published today in the European Journal of Endocrinology, a leading scientific journal for endocrinology.

  • Successful phase II/III trial of new therapy for Addison´s disease

    Helsingborg/ Washington DC June 12th 2009- DuoCort gained promising data from its Phase II/III study for the rare and life threatening disease adrenal insufficiency. DuoCort’s new form of physiological treatment with once daily dosing show improved cardiovascular measures compared to standard hydrocortisone given thrice daily. The company presents the data at the ENDO congress in Washington DC.

Fyll i din epostadress för att följa AQILION AB

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa AQILION AB.

Okej